Full-Time

Field Service Engineer

Deadline 5/21/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$50k - $80.5k/yr

Springfield, IL, USA

Hybrid

Hybrid role with ~25% in-office work and 75% fieldwork.

Category
Hardware Engineering (1)
Required Skills
Inventory Management
Data Analysis
Requirements
  • Vocational/Trade Certificate with preferably 6 years related work experience, OR Associate degree with preferably 4 years related experience OR Bachelor’s degree with preferably 2 years related experience OR High School diploma with preferably 8 years related work experience in customer support, technical support/technical service.
  • Customer service experience, including data analysis and reporting.
  • Strong English verbal and written communication skills.
  • Strong organizational and time-management skills.
  • Proficiency in Microsoft Office.
  • Strong problem-solving skills.
  • Experience with service management systems preferred.
  • Ability to use standard test equipment, including a digital multimeter.
  • Ability to drive customer satisfaction and continuous process improvement.
  • Ability to work in a hybrid office/field environment (approximately 25% office / 75% field).
  • Ability to travel on short notice, including frequent air travel.
  • Ability to operate a company vehicle with a valid driver’s license.
  • Flexibility to work weekends and off-hours as needed to support customer and business needs.
  • Ability to perform physical tasks including heavy lifting, prolonged standing, bending, and related activities.
  • Commitment to following safety rules and procedures at all times.
  • Proper use of personal protective equipment (PPE) and safety devices as required.
  • Participation in incident investigations related to health, safety, or environmental matters.
Responsibilities
  • Provide technical support to internal and external customers through the Customer Support Call Center
  • Manage assigned territory schedules and perform installation, operation, repair, upgrades, and preventative maintenance of equipment
  • Develop and implement preventative maintenance programs and maintain accurate performance and service records
  • Manage regional schedules to support all technical and engineering activities for serviced products
  • Respond to emergency service requests by identifying root causes, troubleshooting, and implementing corrective actions
  • Provide guidance and technical support to customers, including physicians, nurses, hospital biomedical engineers, field service specialists, and representatives
  • Proactively manage customer expectations before, during, and after service interactions to ensure customer satisfaction
  • Act as a customer advocate, representing customer needs internally and assisting with resolution of satisfaction-related concerns
  • Complete all required documentation, administrative tasks, and paperwork in accordance with policies and procedures
  • Ensure timely and accurate updates in the Service Management System, including work orders and service requests
  • Process all RMA returns and track parts and equipment usage
  • Manage assigned inventory and perform required audits
  • Complete all required training related to supported products, systems, and processes
  • Support installation and service of products used in clinical trials, external evaluations, regulatory testing, or similar activities
  • Communicate business-related issues, risks, and opportunities to management as appropriate
  • Participate in incident investigations as required
  • Ensure personal compliance with all Federal, State, local, and company regulations, policies, and procedures
  • Adhere to Johnson & Johnson environmental, health, and safety policies and guidelines; immediately escalate any violations, deviations, or hazardous conditions
  • For roles with supervisory responsibilities, ensure team members comply with health, safety, and environmental requirements and have appropriate resources
  • Perform other duties as assigned
Desired Qualifications
  • Academic qualification in engineering or equivalent experience
  • Knowledge of servicing principles, practices, and procedures
  • Experience in the medical device industry
  • IT integration skills

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue hit $24.1 billion, up 9.9%, raising 2026 forecast to $100.8 billion.
  • Nipocalimab gains FDA Priority Review for autoimmune hemolytic anemia and myasthenia gravis efficacy.
  • Shockwave C2 Aero launches in US and Japan targeting 315 million calcified CAD patients.

What critics are saying

  • Stelara sales plunge 60% to $656 million in Q1 2026 post-patent expiration, creating $2.3 billion hole.
  • Icotyde stalls at 1,500 prescriptions, missing oncology targets by Q3 2026.
  • CAPLYTA faces Invega Sustenna competition, achieving under 10% adoption by mid-2027.

What makes Johnson & Johnson unique

  • J&J unites Innovative Medicine and MedTech under single brand since September 2023.
  • DARZALEX and TREMFYA dominate oncology and immunology with $57 billion pharma sales in 2024.
  • CARTO System leads electrophysiology for 30 years with AI-powered CARTOSOUND SONATA.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Johnson & Johnson who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Company News

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

Yahoo Finance
Apr 1st, 2026
J&J takes over NBTXR3 Phase III as Nanobiotix shifts to Curadigm, secures runway into early 2028

Nanobiotix has transferred full operational and financial responsibility for its NBTXR3 radioenhancer programme to Johnson & Johnson, with Phase III head-and-neck results expected in H1 2027 and Phase II lung cancer data anticipated in early 2027. The company is pivoting towards its Curadigm nanoprimer platform, filing four patents, starting GMP manufacturing and signing over 20 material transfer agreements with partners. Additional Curadigm data is expected before summer's end. An amended Janssen licence removing most Phase III funding obligations, combined with a royalty financing of up to $71 million, extends Nanobiotix's cash runway into early 2028. The company reported EUR 32.6 million revenue in 2025, reduced R&D spending to EUR 23.1 million, and EUR 52.8 million cash at year-end.